Apogee Therapeutics (NASDAQ:APGE) Trading 5.3% Higher

Apogee Therapeutics, Inc. (NASDAQ:APGE) traded up 5.3% during trading on Thursday . The company traded as high as $38.31 and last traded at $38.31. 199,137 shares traded hands during mid-day trading, a decline of 64% from the average session volume of 548,840 shares. The stock had previously closed at $36.37.

Analyst Ratings Changes

A number of analysts recently commented on the stock. Bank of America assumed coverage on shares of Apogee Therapeutics in a report on Friday, May 10th. They issued a “buy” rating and a $80.00 target price on the stock. Guggenheim boosted their target price on shares of Apogee Therapeutics from $44.00 to $91.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. Jefferies Financial Group boosted their target price on shares of Apogee Therapeutics from $37.00 to $75.00 and gave the stock a “buy” rating in a report on Wednesday, March 6th. Stifel Nicolaus boosted their price target on shares of Apogee Therapeutics from $46.00 to $95.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. Finally, Wedbush restated an “outperform” rating and set a $87.00 price target on shares of Apogee Therapeutics in a report on Monday, May 13th. Eight analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $73.00.

Apogee Therapeutics Stock Down 0.1 %

The stock’s 50-day moving average is $47.41 and its 200 day moving average is $43.34. The stock has a market capitalization of $2.22 billion and a PE ratio of -7.24.

Apogee Therapeutics (NASDAQ:APGE) last released its earnings results on Monday, May 13th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.60) by ($0.04). As a group, equities research analysts forecast that Apogee Therapeutics, Inc. will post -2.64 EPS for the current year.

Hedge Funds Weigh In On Apogee Therapeutics

Several large investors have recently bought and sold shares of the stock. EntryPoint Capital LLC raised its stake in Apogee Therapeutics by 44.7% during the 1st quarter. EntryPoint Capital LLC now owns 1,997 shares of the company’s stock valued at $133,000 after purchasing an additional 617 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Apogee Therapeutics by 28.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,155 shares of the company’s stock valued at $475,000 after buying an additional 1,600 shares in the last quarter. SG Americas Securities LLC lifted its holdings in shares of Apogee Therapeutics by 34.0% during the 4th quarter. SG Americas Securities LLC now owns 6,607 shares of the company’s stock worth $185,000 after acquiring an additional 1,676 shares during the period. Ameritas Investment Partners Inc. lifted its holdings in shares of Apogee Therapeutics by 111.2% during the 1st quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company’s stock worth $274,000 after acquiring an additional 2,172 shares during the period. Finally, Kennedy Capital Management LLC bought a new position in shares of Apogee Therapeutics during the 1st quarter worth about $212,000. 79.04% of the stock is currently owned by institutional investors and hedge funds.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.